| Jul 31 |
Grifols: Q2 Earnings Snapshot
|
| Jul 31 |
GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
|
| Jul 30 |
Grifols takes $494M hit from Shanghai RAAS stake
|
| Jul 30 |
Grifols Cuts Chinese Stake Value by €457 Million After Audit
|
| Jul 29 |
Grifols receives expanded XEMBIFY label in U.S.
|
| Jul 29 |
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
|
| Jul 16 |
Grifols: Going Private? Brookfield On The Scene
|
| Jul 16 |
Grifols: Stay On The Sidelines
|
| Jul 12 |
Grifols board to back potential go-private deal
|
| Jul 12 |
Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%
|
